Affiliation of authors: Department of Health Research and Policy, Stanford University School of Medicine, CA.
Correspondence to: Atsuko Shibata, M.D., Ph.D., Department of Health Research and Policy, Stanford University School of Medicine, HRP-Redwood Bldg., Rm. T211, Stanford, CA 943055405 (e-mail: ashibata{at}stanford.edu).
Previously, we reported trends of prostate cancer incidence and mortality among white men in the United States (U.S.) and men in the United Kingdom (U.K.) during the period 19681995 (1). In that brief communication, we noted a striking excess in the U.S. incidence rates compared with the U.K. rates, despite similar mortality rates in the two populations. Since prostate cancer screening by prostate-specific antigen (PSA) has been more common in the U.S. than in the U.K. (2), the data suggested to us that these differences were due to differences in screening.
A subject of ongoing debate is the diagnosis and treatment of early-stage prostate cancer detected via intensive screening. The pros and cons of such screening must be evaluated by its impact on prostate cancer mortality, as assessed in randomized, controlled, long-term trials. Meanwhile, close monitoring of population-based mortality rates may provide clues (3). Accordingly, we updated the incidence and mortality rates described above with data since 1995.
Fig. 1 shows the incidence and mortality rates for U.S. men (white) and for U.K. men (all races) from 1986 to the most recent years for which statistics are available. All rates (for both the U.S. and the U.K.) were standardized to the age distribution of the European standard population (4). For U.S. white men, the incidence rates were calculated with the use of data from nine Surveillance, Epidemiology, and End Results (SEER)1 registries (San FranciscoOakland, CA; Connecticut; Detroit, MI; Hawaii; Iowa; New Mexico; Seattle, WA; Utah; and Atlanta, GA) (5), whereas the mortality rates were calculated with the use of data for the entire U.S. (6). For U.K. men, the incidence rates pertain to England and the mortality rates pertain to England and Wales (7).
|
NOTES
1 Editor's note: SEER is a set of geographically defined, population-based, central cancer registries in the United States, operated by local nonprofit organizations under contract to the National Cancer Institute (NCI). Registry data are submitted electronically without personal identifiers to the NCI on a biannual basis, and the NCI makes the data available to the public for scientific research.
Supported in part by Public Health Service grant CA67044 (to A. S. Whittemore) from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.
We thank Arthur Kern for suggesting this update.
REFERENCES
1
Shibata A, Ma J, Whittemore AS. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 1998;90:12301.
2 Hall RR. Radical prostatectomy and prostate cancer screening: the need for national audit and research. Ann R Coll Surg Engl 1994;76:36772.[Medline]
3 Mettlin CJ, Murphy GP. Why is the prostate cancer death rate declining in the United States? [editorial]. Cancer 1998;82:24951.[Medline]
4 CANCER-Mondial. European and world standard population (available online: http://www-dep.iarc.fr/dataava/ewstdpop.htm).
5 National Cancer Institute. CANQUES on the Web, SEER incidence crude rates, 9 registries, 19731998 (available online: http://seer.cancer.gov/ScientificSystems/Canques/).
6 U.S. National Center for Health Statistics. Data Warehouse. Table 292A. Death rates for 282 selected causes, by 5-year age groups, race, and sex: United States, 197998 (rates per 100,000 population) (available online: http://www.cdc.gov/nchswww/datawh/statab/unpubd/mortabs/gmwk292.htm).
7 National Statisticsthe official UK statistics site. STATSTORE: Health and care (available online: http://www.statistics.gov.uk/statbase/datasets2.asp).
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |